DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1771)

Prostate Cancer | Unmet Need | Detailed, Expanded Analysis (US/EU)

Prostate Cancer | Unmet Need | Detailed, Expanded Analysis (US/EU)

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Coming December 2018

Market Outlook

The treatment armamentarium of mCRPC has significantly evolved with the addition of hormonal agents such as Zytiga (Johnson & Johnson/Janssen) and Xtandi (Pfizer/Astellas). These targeted therapies have benefited efficacy outcomes and have favorable safety profiles. The management of mCRPC has been further transformed with the availability of therapeutic vaccine Provenge (Dendreon Pharmaceuticals) and radiopharmaceutical agent Xofigo (Bayer). Nevertheless, an enormous medical unmet need for better-tolerated novel therapies which could prolong overall survival and delay disease progression to a greater extent remains. Our unmet need module analyzes the key drivers of prescribing and identifies the most attractive commercial opportunities for drug developers.


  • What are the treatment drivers and goals for mCRPC?
  • What drug attributes are key influencers, which have limited impact, and which are hidden opportunities for drug developers?
  • How do current therapies perform on key treatment drivers and goals for mCRPC?
  • What are the prevailing areas of unmet need and opportunity in mCRPC?
  • What trade-offs across different clinical attributes and price are acceptable to U.S. and European medical oncologists for a hypothetical new first-line mCRPC therapy?


Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, France, Germany, United Kingdom

Primary research: Survey of 60 U.S. and 30 European medical oncologists to be fielded in August 2018.

Key companies:  Johnson & Johnson/Janssen, Pfizer/Astellas, Dendreon Pharmaceuticals, Bayer, and Sanofi.

Key drugs: Zytiga, Xtandi, Provenge, Xofigo, and Jevtana.

Table of contents

  • Detailed, Expanded Analysis (US/EU)
    • Coming Soon
      • Coming Soon

Coming soon

Already a Client? Log in to access this report.

  • Pub Date: December 2018
  • Author(s): Sudha Malhotra

Purchase Report

Recent reports:
You may also be interested in: